Lymphoma of the Marginal Zone: Its Varieties, Treatment, Prognosis, and Further Details
Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma that accounts for approximately 30% of all lymphoma cases, according to the American Cancer Society (ACS). This disease affects B cells and can manifest in three main forms: Nodal MZL, Extranodal marginal zone B-cell lymphoma, and Splenic MZL.
Infections such as Epstein-Barr, Human Herpesvirus 8, Human T-lymphotropic virus type I, Hepatitis C virus, Chlamydophila psittaci, Borrelia burgdorferi, and Campylobacter jejuni can lead to MZL. In the case of Splenic MZL, there is a link to the hepatitis C virus. Gastric MALT lymphoma, specifically, is associated with an infection with Helicobacter pylori.
The symptoms of MZL may include swollen lymph nodes, a swollen abdomen, excessive fatigue, night sweats, breathing problems, chest pain, flu-like symptoms, frequent illnesses, and more. Diagnosing and treating MZL can be challenging, depending on the stages of each disease. The diagnosis process begins with an extensive evaluation that includes a medical history, lab tests, scans, and biopsy, when possible.
Treatment options for MZL are personalized and often start with immunotherapy and targeted agents. Immunotherapy drugs like rituximab are commonly used, as are targeted agents such as Bruton tyrosine kinase (BTK) inhibitors, including zanubrutinib and acalabrutinib. Chemotherapy regimens like R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, prednisone) may also be employed.
For advanced cases or relapse management, stem cell transplantation and CAR T-cell therapy may be considered. CAR T-cell Therapy, specifically Breyanzi, has received FDA Priority Review for relapsed or refractory MZL, showing high overall and complete response rates in third-line and beyond settings. Clinical trials are actively investigating novel combinations and new drugs aimed at improving outcomes while minimizing toxicity.
Supportive care and management of side effects are integral to treatment, often with additional medications tailored to patient needs. The 5-year survival rates for MZL are 88.7% for MALT lymphomas, 79.7% for splenic MZL, and 76.5% for nodal MZL. These figures are estimates and based on previous studies or treatments.
Treatment for non-gastric MALT depends on the location of the cancer. For example, radiation therapy alongside antibiotics may be used for cancers in the eye. Watchful waiting, radiation therapy, surgery, immunotherapy, or chemotherapy may be recommended for advanced non-gastric MALT.
Family history or genetics, exposure to radiation, chemotherapy drugs, herbicides, and insecticides can be risk factors for MZL. Most cases of MZL occur in individuals over the age of 60. MZL may develop due to autoimmune conditions, such as Sjörgen syndrome and chronic autoimmune thyroiditis.
In conclusion, the treatment of MZL is a personalized journey, often starting with immunotherapy and targeted agents, with chemotherapy or advanced therapies like CAR T cells for relapsed or refractory disease. Access to clinical trials can provide additional options and cutting-edge treatments. These modalities collectively address the heterogeneity of MZL subtypes and patient statuses.
- Medical-conditions like Sjörgen syndrome and chronic autoimmune thyroiditis may lead to the development of Marginal Zone Lymphoma (MZL), which is a type of cancer that accounts for approximately 30% of all lymphoma cases.
- In some cases of Splenic MZL, the hepatitis C virus is associated with the disease, and in gastric MALT lymphoma, an infection with Helicobacter pylori is specifically associated.
- The treatment of MZL may involve the use of science-backed medical strategies such as immunotherapy drugs like rituximab, targeted agents such as Bruton tyrosine kinase (BTK) inhibitors, chemotherapy like R-CHOP, stem cell transplantation, CAR T-cell therapy, and supportive care to manage side effects.
